Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
Status:
RECRUITING
Trial end date:
2030-06-30
Target enrollment:
Participant gender:
Summary
This study is a prospective, single-arm, phase 2 clinical trial assessing the feasibility, efficacy, and safety of the PD-L1 inhibitor Benmelstobart (TQB2450) as an adjuvant therapy regimen in patients with pathologic stage IB, IASLC grade 3 invasive lung adenocarcinoma without EGFR active mutations or ALK rearrangement.